Skip to main content

Trifork launches Synq to reduce costly equipment downtime with remote maintenance and repair

Press release Trifork launches Synq to reduce costly equipment downtime with remote maintenance and repair Application uses Apple Vision Pro to connect technicians to field crews in real time March 5, 2026 – Copenhagen & Chicago – Trifork, the leading spatial computing solutions provider trusted by companies like Apple, Porsche, and Lufthansa Group, today announced the launch of its proprietary enterprise application, Synq, enabling fully remote technical maintenance and repairs. Synq alleviates the need for technicians to be on site, making it ideal for manufacturing environments and workflows across automotive, aviation, transportation, logistics, and other industries. As a pioneer in spatial computing across medtech, retail showroom experiences, and employee training, Trifork is launching Synq with Fortune 500 companies, including...

Continue reading

CMS(867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity

SHENZHEN, CHINA, March 05, 2026 (GLOBE NEWSWIRE) — China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals. About CMS-D008 CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that...

Continue reading

Boskalis 2025 annual results: strong financial performance with EBITDA of EUR 1.3 billion and net profit of EUR 775 million

Boskalis_crane vessel Bokalift 1 in wind farmBoskalis_crane vessel Bokalift 1 in wind farmPapendrecht, 05 March 2026  ‎KEY FIGURES 2025Revenue: EUR 4.5 billion(2024: EUR 4.4 billion)EBITDA: EUR 1.3 billion(2024: EUR 1.3 billion)Operating Result: EUR 886 million(2024: EUR 782 million)Net profit: EUR 775 million(2024: EUR 781 million)Order book: EUR 7.0 billion(2024: EUR 7.0 billion)Royal Boskalis B.V. (Boskalis) in 2025 posted a strong financial performance once again. The full-year group revenue, EBITDA, and year-end orderbook were all slightly higher than the all-time highs in 2024. Revenue amounted to EUR 4.5 billion, an increase compared to 2024, with growth contributions from both the Offshore Energy and Towage & Salvage divisions. Adjusted for (de)consolidation and currency effects, the year-on-year...

Continue reading

Preliminary Statement of Results for the year ended 31 December 2025

Preliminary Statement of Results for the year ended 31 December 2025 Irish Continental Group (ICG), the leading Irish-based maritime transport group, reports its financial performance for the year ended 31 December 2025. HighlightsFinancial Summary          2025 2024 Change  Revenue   €666.7m €603.8m +10.4%  EBITDA   €150.6m €133.5m +12.8%  Operating profit   €85.6m €69.1m +23.9%  Basic earnings per share   46.6c 36.3c +28.4%  Final dividend   10.95c 10.43c +5.0%  Net debt   €(256.1)m €(162.2)m +57.9%  Net debt (pre-IFRS 16)   €(133.5)m €(55.1)m 142.3%  ROACE   18.9% 16.9% 2.0%pts                 Volume movements      2025‘000 2024‘000 Change  RoRo units 816.7 767.2 +6.5%Cars 679.7 707.3 (3.9%)Containers shipped (teu) 370.0 317.8 +16.4%Port lifts 360.9 339.4 +6.3%           This...

Continue reading

Admiral Group Plc Full Year 2025 Results

5 March 2026 2025 Results Highlights Admiral Group reports record profits for 2025 with strong contributions from across the Group  31 December 2025 31 December 2024 % change vs. 2024Group profit before tax from continuing operations2 £957.9m £826.5m +16%Earnings per share from continuing operations2 247.4p 212.8p +16%       Dividend per share 205.0p 192.0p +7%Return on equity1 53% 56% -3pts       Group turnover1 2 £5.90bn £5.95bn -1%Insurance revenue2 £4.98bn £4.55bn +9%       Group risks1 2 11.8m 11.0m +7%UK insurance risks1 9.6m 8.8m +9%European insurance risks1 1.9m 2.0m -2%Admiral Money gross loan balances £1.46bn £1.17bn +24%       Solvency ratio (post-dividend)1 193% 203% -10pts1 Alternative Performance Measures – refer to the end of the report for definition and explanation. 2...

Continue reading

MBWS Becomes the Exclusive Distributor of Flor de Caña Rum in France

Charenton-le-Pont, March 5th , 2026 MBWS Becomes the Exclusive Distributorof Flor de Caña Rum in France Marie Brizard Wine and Spirits and Flor de Caña announce the conclusion of an exclusive distribution agreement covering the brand’s premium rum portfolio on the French market. This strategic partnership marks a new milestone in the shared ambition of both groups to further develop the brand in France. As of 16 March 2026, MBWS will, under this partnership, handle the distribution of the entire Flor de Caña range. The award-winning portfolio includes iconic and core expressions such as the 4-year, 12-year, 14-year and 18-year-old rums, prestigious references including the 25-year and 30-year – V Generaciones editions, as well as innovative rum-based spirit drinks, notably Coco and Spresso, designed to meet evolving consumer needs. A 5th-generation,...

Continue reading

Cabka delivers disciplined SHIFT execution in 2025 with EBITDA growth and significant net debt reduction

Key Financial Developments 2025Revenues of €180.0 million, down 1% yoy (2024: €181.9 million), with improved momentum in H2 Gross margin improved to 51.3% (2024: 50.9%), due to an improved product mix, higher operational efficiency, and centralized material purchasing strategy  Operational EBITDA increased to €21.1 million in 2025 (2024: €20.5 million), an EBITDA margin of 11.7% (2024: 11.3%) Net loss improved to €-7.4 million (2024: €-9.4 million) supported by SHIFT plan execution, which reduced the personnel and operational expenses by €3 million year over year Net working capital at €28.3 million or 15.7% of sales (2024: €26.7 million or 14.7% of sales) Net debt decreased to €62.6 million (2024: €71.8 million). Net debt/EBITDA year end 2025 decreased to 2.7x from 3.2x (year-end 2024) Total CAPEX materially reduced to €11.7 million...

Continue reading

Fiscal year 2025: RENK Group AG achieves annual targets with new record revenue and order backlog

Fiscal year 2025: RENK Group AG achieves annual targets with new record revenue and order backlogRecord revenue of €1.37 billion (+19.8% year on year), fueled by strong growth in the defense business (+24.0% year on year) Adjusted EBIT of €230 million (+21.7% year on year) at upper end of forecast range with improved margin of 16.9% (+0.3 percentage points year on year) New record order intake of €1.57 billion underscores consistently high demand for RENK Group AG’s mission-critical propulsion solutions Total order backlog reaches new all-time high of €6.68 billion (2024: €4,96 billion) Proposed dividend of €0.58 per share – an increase of 38% compared to the previous year Outlook: Further increase in revenue to over €1.5 billion and adjusted EBIT of between €255 million and €285 million currently expected for fiscal year 2026Augsburg,...

Continue reading

BioVersys to Report Its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call

BASEL, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) — BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today the reporting of its Full Year 2025 financial results, along with a business update and the hosting of an investor, analyst and media conference call. The company will publish its Full Year 2025 financial results on March 18, 2026. On the reporting date, BioVersys will issue a press release at 7:00 AM CET / 2:00 AM ET. Following the release, BioVersys will host a conference call and webcast on March 18, 2026 at 2:00 PM CET / 9:00 AM ET where management will review the financial results, provide a business update, outline its strategic...

Continue reading

WISeKey Reports FY 2025 Preliminary Financial Results

WISeKey Reports FY 2025 Preliminary Financial Results Subsidiary SEALSQ Delivers 66% Year-Over-Year Revenue Growth and Advances Global Quantum-Secure Semiconductor Ecosystem Geneva, Switzerland, March 5, 2026 – Ad hoc announcement pursuant to Art. 53 LR – WISeKey International Holding Ltd (“WISeKey” or “WISeKey Group”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today reported key operational and financial metrics for the fourth quarter (“Q4”) and full year (“FY”) ended December 31, 2025. These figures include preliminary results from its subsidiary, SEALSQ Corp (NASDAQ: LAES) (“SEALSQ”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products. WISeKey holds 52% of the voting rights in SEALSQ, enabling...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.